We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser’s cookie settings at any time. Please review our privacy policy for more information. OK
For biotech, the retention value of options is currently in jeopardy. Here are several key points to weigh if your company is considering strong action.